June 18, 2012
Takeda Pharmaceutical Company Limited
Pfizer Japan Inc.
Osaka and Tokyo, Japan, June 18, 2012—Takeda Pharmaceutical Company Limited (“Takeda”) and Pfizer Japan Inc. (“Pfizer”) announced today that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth K.K. and currently distributes under an exclusive distribution agreement with Pfizer, and that Pfizer, the manufacturer of the products, will begin selling them thereafter. In addition, Takeda will continue to distribute the pneumococcus vaccine Prevenar® for infants and young children and hemophilia B drug BeneFIX® (generic name: nonacog alfa) after January 2013.
Aside from this exclusive distribution agreement, the two companies agreed in February 2011 to extend the term of co-promotion agreement of the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept), the marketing of which Takeda will continue.
Takeda and Pfizer will remain committed to the prevention and treatment of diseases by providing drugs that meet the needs of patients and medical professionals through their successful partnership.
The 13 products, the marketing of which by Takeda will terminate on December 31, 2012 and be commenced by Pfizer in January, 2013
|Isovorin®, active folate||Artane®, treatment for parkinsonian syndrome|
|Amoxan®, treatment for depression||Torisel®, anticancer agent|
|Napageln®, transdermal antiinflammatory drug||Photofrin®, treatment for photodynamic therapy|
|Premarin®, conjugated estrogens||Mylotarg®, anticancer agent|
|Minomycin®, antibiotic||Methotrexate®, folate metabolism blocker|
|Rheumatrex®, treatment for rheumatoid arthritis||Leucovorin®, anti-folate metabolism blocker|
|Wypax®, minor tranquilizer|
The Products which Takeda will continue to distribute after January, 2013
|Prevenar®, pneumococcus vaccine for infants and young children||BeneFIX®, treatment for hemophilia B|
|Enbrel®, treatment for rheumatoid arthritis|
*Any impact that the termination of this exclusive distribution might have has been factored into Takeda’s outlook for consolidated results for the fiscal year ending March 31, 2013, which was announced on May 11, 2012.
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Pfizer, a world’s leading research-based pharmaceutical, is focusing on research, development and manufacturing of medicines for people and animals. We strive to support people’s lifelong health and well-being and contribute to improving quality of life through innovative and valuable products globally.
To learn more about our activities, please visit us at www.pfizer.com < http://www.pfizer.com/ > (Pfizer Inc.) and www.pfizer.co.jp < http://www.pfizer.co.jp/ > (Pfizer Japan Inc.)
# # #